Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Gilead teams with Goldfinch for kidney disease drugs

by Lisa M. Jarvis
May 11, 2019 | A version of this story appeared in Volume 97, Issue 19

 

In a deal worth $109 million, Gilead Sciences has teamed up with Goldfinch Bio to develop treatments for diabetic kidney disease and other rare kidney disorders. The pact gives Gilead exclusive rights to license Goldfinch’s kidney disease patient registry, which ties together patient clinical profiles and genomic, transcriptomic, and proteomic data. Goldfinch will expand that data set to include gene sequences from people with diabetes with and without kidney disease with the goal of identifying new drug targets. Up to 40% of people with diabetes have kidney disease, which can cause myriad health complications.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.